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ABSTRACT
A case of exuberant acroosteolysis and 
subcutaneous tissue calcinosis in the 
absence of  skin involvement is present-
ed. Different hypotheses are discussed 
following the clinical unfolding of the 
case in practice. 
Introduction
Acroosteolysis and calcinosis are a ne-
glected problem in rheumatic diseases. 
We herein discuss and analyse a case 
presented over three vignettes.
Case vignette I  
A 71-year-old female, presented with 
bilateral arthralgia and swelling of the 
wrists, MCPs, PIP, DIP and MTP joints 
evolving with variable intensity for ﬁf-
teen years. She described typical bilat-
eral Raynaud’s phenomenon over the 
past four years, but denied any other 
relevant signs or symptoms.
The joints were tender and presented 
bony nodules that were inﬂamed over 
the right elbow and ankle. Facial tel-
angiectasias (Fig. 1) were noted and no 
ﬁbrosis was detectable on the hands (Fig. 
2). General examination was normal.
X-rays revealed acroosteolysis in the 
hands (Fig. 3A)  the knees, feet and 
Achilles tendon (Figs. 3B, C, D).
Discussion
Acroosteolysis consists of the resorp-
tion of bone extremities, more fre-
quently the distal phalanxes. 
It may be part of primary familial syn-
dromes, which tend to follow an auto-
somal hereditary pattern. Acroosteoly-
sis of distal phalanxes is usually found 
in all these conditions (Table I) but may 
also be accompanied by other bone 
modiﬁcations not seen in our patient. 
Acroosteolysis may also develop as a 
result of local repetitive trauma (ther-
mal, electrical and mechanical) or pe-
ripheral ischemia. It has been reported 
to affect 1 to 3% of people chronically 
exposed to vinil chloride (9).
It has been described in association 
with a variety of cutaneous diseases 
(psoriasis, leprosy, bullous epidermoly-
sis, cutaneous porphiria, síﬁlis and pit-
iríasis rubra), metabolic diseases (gout, 
hyperparathyroidism, osteomalacia and 
diabetes mellitus) and neurological 
conditions (syringomyelia and sympa-
thetic reﬂex dystrophy). Occasionally, 
acrosteolysis has been interpreted as 
a secondary manifestation to tumours, 
such as lung cancer, Sésary’s syndrome 
and lymphoma (9). 
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Fig. 2.  The digits did not present edema or ﬁbro-
sis; the skin can be pinched without any problem.
Fig. 1. Teleangectasias are visible on the face 
of the patient.
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More commonly, however, acrosteoly-
sis is observed in patients with con-
nective tissue diseases, with special 
emphasis on systemic sclerosis (SSc). 
However, patients with systemic lupus 
erythematosus, mixed connective tis-
sue disease, Sjögren’s syndrome, rheu-
matoid and psoriatic arthritis and sar-
coidosis can also present resorption of 
distal and proximal phalanxes (9-11). 
Tissue calcinosis (deposition of insolu-
ble calcium salts in soft tissues) can oc-
cur as a result of hypercalcemia, usually 
in the context of hyperparathyroidism. 
In idiopathic conditions, with normal 
circulating levels of calcium and phop-
shorus, nodular or milia-like deposits 
of calcium salts are found in the subc-
taneous tissue (more commonly of the 
head or the extremities, the scrotum or 
the periphery of joints). This situation 
affects young people or patients with 
Down’s syndrome (12-13). 
However, in the absence of serum cal-
cium abnormalities, calcinosis usually 
affects sites of previous lesions. This 
so called “dystrophic calcinosis” can 
be found in tumours and sites of trauma 
or infection but also in scarring tissue 
of patients with SLE, systemic sclero-
Fig. 3 A. Acroosteolysis of distal phalanges and 
extensive calcinosis are visible; 
B, C, D: calcinosis of the Achilles tendon, feet 




Table I. Hereditary syndromes causing distal phalanx osteolysis (1-8). 
Condition Hereditary pattern Age at onset Additional clinical features
Hadju-Cheney’s syndrome Dominant autosomal Infancy Cranial and facial anomalies; premature loss of teeth and 
   micrognathia; short stature
Mandibuacral syndrome Recessive autosomal Adolescence/young Mandible and clavicle hypoplasia; cutaneous atrophy; 
  adulthood lipodistrophy
Schinz disease Dominant autosomal Adolescence/ young Recurrent ﬁnger ulcerations 
  adulthood 
Neurogenic acroosteolysis Dominant or recessive Childhood Sensorial neuropathy; Mal perforans; vasomotor disfunction; 
 autosomal   hyperhydrosis
Werner’s syndrome Recessive autosomal Adolescence/ young Precocious ageing; wrinkled skin; baldness; cataracts; muscular 
  adulthood atrophy; diabetes mellitus
Pachydermoperiostsis Recessive autosomal Adolescents/adults Finger clubbing, Periostosis, arthritis, seborrhoea, cutis
(primary hypertrophic    verticis gyrate
osteoarthropathy)
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sis, dermatomyositis, mixed connec-
tive tissue disease and Ehler-Danlos 
syndrome (12-16). 
In summary, potential causes of con-
comitant acroosteolysis and tissue cal-
cinosis appear to be limited to systemic 
sclerosis, SLE, mixed connective tissue 
disease and hyperparathyroidism.
Case vignette II   
Laboratory evaluation showed normal 
full blood count and urinalysis, nor-
mal C-reactive protein (0.14mg/dl) and 
raised ESR (36mm). Serum calcium 
(9.4g/dl), phosphorus (3.7mg/dl), al-
bumin (4.0g/dl), alkaline phosphatase 
(70U/L), parathormone (73.6 pg/ml) and 
thyroid hormones were all within the 
normal range.
Chest x-ray revealed a reticular pattern 
suggesting interstitial ﬁbrosis (Fig. 4). 
Hyperparathyroidism may be excluded 
on the basis of normal serum and urine 
calcium and phosphate, as well as se-
rum parathormone. However, clinical 
criteria were missing for any connec-
tive tissue diseases.
Acroosteolysis makes SSc a major di-
agnostic hypothesis corroborated also 
by calcinosis. The major problem with 
this diagnosis in the present case is 
the absence of skin involvement and 
the late onset of Raynaud’s phenom-
enon. The patient did not present other 
symptoms or signs that would rein-
force this hypothesis, such as dyspnea 
or dysphagia. 
The patient did not satisfy the ACR 
criteria for SSc classiﬁcation which 
require the ﬁnding of either the sole 
major criterion (SSc proximal to meta-
carpophalangeal or metatarsophalan-
geal joints) or two or more of the minor 
criteria (sclerodactily, digital pitting 
scars, bibasilar pulmonary ﬁbrosis) 
(17). Only one of the minor criteria 
was present in this case. Limitations 
of ACR criteria have been pointed out, 
especially regarding lack of sensitivity 
in limited cutaneous SSc subset (18). 
Abrams et al. described for the ﬁrst 
time in 1954 a rare form of SSc (19) 
characterized by the presence of viscer-
al manifestations without skin changes. 
The term SSc sine scleroderma (SSss) 
was coined in 1962 by Rodnan e Fen-
nel (20). The largest case series, was 
published in 2000 (21) and included 48 
cases of SSss representing 9% of 555 
SSc patients. Based on this series, the 
authors proposed a set of diagnostic 
criteria for SSss (Table II).
Further investigations of our patient 
show that she satisﬁes these criteria. 
Case vignette III
IgG rheumatoid factor (47 UI/ml, 
nephelometry), antinuclear antibodies 
(1:640 speckled and nucleolar pattern) 
and SSA were positive.While anti-cen-
tromere, anti-topo I or anti-RNP anti-
bodies were negative. 
Chest high-resolution CT-scan revealed 
areas of ground-glass in the lower lobes 
(Fig. 5). Respiratory function tests re-
vealed a reduced alveolar diffusion 
(DLCO/ VA – 66.6%). Oesophageal ma-
nometry was normal. Cardiac echocar-
Fig. 4.  Chest x-ray shows a reticular pattern.
Table II. Diagnostic criteria for systemic 
sclerosis sine scleroderma according to 
Poormoghim (21).
1. Raynaud’s phenomenon or peripheral vascu-
lar equivalent (digital pitting scars, digital-tip 
ulcers, digital-tip gangrene or abnormal nail-
fold capillaries)
2. AND
3. Positive antinuclear antibodies 
4. PLUS one or more of the following
a. Distal oesophageal hypomotility
b. Small bowel hypomotility 
c. Pulmonary interstitial ﬁbrosis
d. Primary pulmonary arterial hypertension 
(without ﬁbrosis)
e. Renal failure consistent with scleroderma 
renal crisis 
f. Cardiac involvement typical of SS
5. Absence of any other connective tissue dis-
ease as a cause of 1, 2 or 3. 
Fig. 5. Chest high resolution computed tomo-
graphy shows the ground glass of lower lobes.
Fig. 6. Nailfold videocapillaroscopy: the pattern 
shows an avascular area. 
Table III. Clinical and serologic comparison between SSc sine scleroderma and limited 
SSc according to Poormonghim (21).
 SSss lcSS
ANA 94% 94%
Anti-centromere  31% 54%
Anti-RNA polymerase III 6% 1%
Other non-SSc associated antinuclear antibodies 44% 14%
Pulmonary involvement 68% 65%
Primary pulmonary arterial hypertension (PPAH) 23% 13%
PPAH as cause of death 52% 24%
S-58
CASE REPORT Exuberant calcinosis and acroosteolysis / M.J. Saavedra et al.
diography did not detect increase in 
mean pulmonary pressure.
Capillaroscopy showed dysmorphic 
capillaries, megacapillaries, avascular 
areas and haemorrhages (22) (Fig. 6). 
Poormonghim’s series suggests that 
anti-centromere antibodies are less fre-
quent in SSss than in the typical limited 
SSc subset, whereas other antibodies 
usually not related to SSc are more fre-
quently present (Table III). The preva-
lence of pulmonary hypertension was 
higher in the SSss being the most fre-
quent cause of death. 
In 2002, Slobodin et al. (23) suggested 
the recognition of two different types 
of SSss. Some patients present with 
Raynaud’s phenomenon, oesophageal 
dysmotility and antinuclear antibod-
ies in the absence of previous connec-
tive tissue disease of any sort. Such 
cases, which represented the majority 
of Poormoghim’s series, could be seen 
as incomplete forms of limited SSc and 
had a good prognosis. In other patients, 
features of SSss develop in the context 
of a previous undifferentiated connec-
tive tissue disease. This condition may 
be associated with a more aggressive 
course and SSc can be expected to ap-
pear in up to 60% of cases in the ﬁrst 7 
years. This latter pattern could be seen 
as SSc before (rather than sine) the 
onset SSc.
Our case seems to ﬁt best in the ﬁrst 
pattern even if it does not fulﬁl the 
ACR SSc criteria (17, 18). Although 
SSc is a lethal disease (24), the visceral 
involvement can be considered benign 
until now. This is in contrast with a 
very aggressive arthritis and exquisite-
ly exuberant calcinosis and acroosteol-
ysis, without skin involvement, twelve 
years after the onset of  ﬁrst symptoms 
of disease.
It is interesting to note that, in our pa-
tient, Raynaud’s phenomenon started 
eight years after the proven onset of 
acroosteolysis. This would question the 
view according to which acroosteoly-
sis in SSc is an ischemic consequence 
(10). Calcinosis has been proposed as 
a potential factor for acroosteolysis 
through induction of subchondral bone 
infarction (9, 10).
In conclusion, this case points out the 
importance of acroosteolysis and cal-
cinosis as two important clinical signs 
that should induce  the clinician to care-
fully analyse the whole case in order to 
best perform the differential diagnosis 
in the ﬁeld of rheumatic, metabolic and 
congenital diseases.  
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